Cybin CEO to Speak at Oppenheimer Healthcare Conference

Ticker: HELP · Form: 6-K · Filed: May 1, 2025 · CIK: 1833141

Cybin INC. 6-K Filing Summary
FieldDetail
CompanyCybin INC. (HELP)
Form Type6-K
Filed DateMay 1, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: conference-participation, healthcare, psychedelics

TL;DR

Cybin CEO Drysdale speaking at Oppenheimer Healthcare Conf May 15th - expect pipeline updates.

AI Summary

Cybin Inc. announced on May 1, 2025, its participation in the 28th Annual Oppenheimer & Co. Inc. Healthcare Conference. CEO Doug Drysdale is scheduled to participate in a fireside chat on May 15, 2025, at 11:00 AM ET, to discuss the company's progress in psychedelic-based therapeutics.

Why It Matters

This participation provides Cybin with a platform to update investors and the healthcare community on its drug development pipeline and strategic initiatives.

Risk Assessment

Risk Level: medium — Participation in a conference is a standard disclosure, but the company operates in the highly regulated and speculative field of psychedelic therapeutics.

Key Players & Entities

FAQ

What is the specific date and time of the fireside chat?

The fireside chat is scheduled for May 15, 2025, at 11:00 AM ET.

Who will be representing Cybin Inc. at the conference?

CEO Doug Drysdale will be participating in the fireside chat.

Which conference is Cybin Inc. participating in?

Cybin Inc. is participating in the 28th Annual Oppenheimer & Co. Inc. Healthcare Conference.

What is the purpose of Cybin's participation?

The purpose is to discuss the company's progress in psychedelic-based therapeutics.

What is Cybin Inc.'s principal executive office address?

Cybin Inc.'s principal executive offices are located at 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on May 1, 2025 by Doug Drysdale regarding CYBIN INC. (HELP).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing